No evidence for PALB2 methylation in high-grade serous ovarian cancer

被引：9

作者：

Mikeska, Thomas ^{[1
,2
]}

Alsop, Kathryn ^{[3
,4
]}

Mitchell, Gillian ^{[5
]}

Bowtell, David D. L. ^{[2
,3
,4
,6
]}

Dobrovic, Alexander ^{[1
,2
,6
]}

机构：

[1] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, East Melbourne, Vic, Australia

[2] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia

[3] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia

[4] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia

[5] Peter MacCallum Canc Ctr, Familial Canc Ctr, East Melbourne, Vic, Australia

[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia

来源：

JOURNAL OF OVARIAN RESEARCH | 2013年 / 6卷

基金：

英国医学研究理事会;

关键词：

DNA methylation; Ovarian cancer; Fanconi anaemia; PALB2; MS-HRM; DNA METHYLATION; BREAST; GENE; PATTERNS;

D O I：

10.1186/1757-2215-6-26

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: High-grade serous ovarian cancers are a distinct histological subtype of ovarian cancer often characterised by a dysfunctional BRCA/Fanconi anaemia (BRCA/FA) pathway, which is critical to the homologous recombination DNA repair machinery. An impaired BRCA/FA pathway sensitises tumours to the treatment with DNA cross-linking agents and to PARP inhibitors. The vast majority of inactivating mutations in the BRCA/FA pathway are in the BRCA1 and BRCA2 genes and occur predominantly in high-grade serous cancer. Another member of the BRCA/FA pathway, PALB2 (FANCN), was reported to have been inactivated by DNA methylation in some sporadic ovarian cancers. We therefore sought to investigate the role of PALB2 methylation in high-grade serous ovarian cancers. Finding: PALB2 methylation was investigated in 92 high-grade serous ovarian cancer samples using methylation-sensitive high-resolution melting analysis. DNA methylation of PALB2 was not detected in any of the ovarian cancer samples investigated. Conclusion: Epigenetic silencing by DNA methylation of PALB2 is not a common event in high-grade serous ovarian cancers.

引用

页数：4

共 21 条

[1] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[2] IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer [J].

Anglesio, Michael S. ;

George, Joshy ;

Kulbe, Hagen ;

Friedlander, Michael ;

Rischin, Danny ;

Lemech, Charlotte ;

Power, Jeremy ;

Coward, Jermaine ;

Cowin, Prue A. ;

House, Colin M. ;

Chakravarty, Probir ;

Gorringe, Kylie L. ;

Campbell, Ian G. ;

Okamoto, Aikou ;

Birrer, Michael J. ;

Huntsman, David G. ;

de Fazio, Anna ;

Kalloger, Steve E. ;

Balkwill, Frances ;

Gilks, C. Blake ;

Bowtell, David D. .

CLINICAL CANCER RESEARCH, 2011, 17 (08) :2538-2548

[3] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond [J].

Banerjee, Susana ;

Kaye, Stan .

CURRENT ONCOLOGY REPORTS, 2011, 13 (06) :442-449

[4] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[5] Origins and molecular pathology of ovarian cancer [J].

Bell, DA .

MODERN PATHOLOGY, 2005, 18 :S19-S32

[6] The genesis and evolution of high-grade serous ovarian cancer [J].

Bowtell, David D. L. .

NATURE REVIEWS CANCER, 2010, 10 (11) :803-808

[7]

Candiloro ILM, 2011, METHODS MOL BIOL, V791, P55, DOI 10.1007/978-1-61779-316-5_5

[8] A novel germline PALB2 deletion in Polish breast and ovarian cancer patients [J].

Dansonka-Mieszkowska, Agnieszka ;

Kluska, Anna ;

Moes, Joanna ;

Dabrowska, Michalina ;

Nowakowska, Dorota ;

Niwinska, Anna ;

Derlatka, Pawel ;

Cendrowski, Krzysztof ;

Kupryjanczyk, Jolanta .

BMC MEDICAL GENETICS, 2010, 11

[9] DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast [J].

Huang, Katie T. ;

Dobrovic, Alexander ;

Yan, Max ;

Karim, Rooshdiya Z. ;

Lee, C. Soon ;

Lakhani, Sunil R. ;

Fox, Stephen B. .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (02) :555-565

[10] The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory [J].

Kurman, Robert J. ;

Shih, Ie-Ming .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (03) :433-443

← 1 2 3 →